Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer
Status:
Recruiting
Trial end date:
2023-12-31
Target enrollment:
Participant gender:
Summary
The primary purpose of this study is to determine the response rate of patients with
recurrent platinum resistant ovarian cancer when treated with oral minoxidil. Secondary
objectives include estimating the time to disease progression while on minoxidil and to
describe the toxicities of minoxidil when used for patients with recurrent platinum resistant
ovarian cancer. An exploratory objective is to evaluate if efficacy of minoxidil is improved
in patients that have the Kir6/SUR complex versus those that do not.